A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (MDM2-p53 antagonist) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma (NCT06058793)
AE, adverse event; DDLPS, dedifferentiated liposarcoma; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; MDM2, murine double minute 2; OR, objective response; OS, overall survival; PFS, progression-free survival; q6w, every 6 weeks; q12w, every 12 weeks; TEAE, treatment-emergent adverse event.